Triple – GS-US-595-6184 Ascent-05
Study #GS-US-595-6184Description
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Interested in this trial? Email [email protected].
Back To Clinical Trials